Background: Metastatic castration sensitive prostate cancer (mCSPC) has different modalities of management. However, with the arrival of abiraterone acetate (AA), the management of this condition has changed to a greater extent.
Aims and Objectives: As a new molecule its effectiveness and safety are being evaluated in our patient population as a prospective observational study for 18 months.
Materials and Methods: This study included 50 patients who were treated with AA according to the treating physician. The overall survival observed at 18 months was 88%.
Results: There was a significant decrease in mean serum prostate-specific antigen level with treatment. About 60% of patients were completely adhered to the treatment. About 94% of patients experienced some form of adverse event and 10% of patients died in this study. Though the molecule has adverse effects, the overall survival of the patients has increased.
Conclusion: The efficacy of AA was observed consistent with the time in mCSPC patients with manageable adverse events.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Download PDF 
Post
